KNSA

Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance

The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

The PSUs shall vest, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

The Performance Share Options (PSO) shall vest and become exercisable, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.

The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is July 1, 2026.

The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

The PSOs shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, July 1, 2026.

Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance

The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

Each share of Class B Ordinary Shares is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one share of Class A Ordinary Shares or one share of Class B1 Ordinary Shares and will automatically convert into Class A Ordinary Shares upon transfer to an unaffiliated party.

Each share of Class B Ordinary Shares is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one share of Class A Ordinary Shares or one share of Class B1 Ordinary Shares and will automatically convert into Class A Ordinary Shares upon transfer to an unaffiliated party.

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

Includes 2,026 restricted share units (each an "RSU") payable solely in Class A ordinary shares ("Class A Ordinary Shares") granted by Kiniksa Pharmaceuticals International, plc. (the "Issuer") to each of Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP"), and Dr. Stephen R. Biggar and M. Cantey Boyd, employees of Baker Bros. Advisors LP (the "Adviser"), on May 29, 2026, pursuant to the Issuer's 2018 Incentive Award Plan, as amended (the "Incentive Award Plan"). The RSUs fully vest on the earlier of May 29, 2027 or the date of the next annual meeting of shareholders of the Issuer, subject to the applicable director's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker, Dr. Biggar and M. Cantey Boyd serve on the Board as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Class A Ordinary Shares reported in column 5 of Table I and the Share Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

Pursuant to the policies of the Adviser, Felix J. Baker, Dr. Biggar and M. Cantey Boyd do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified share options exercisable solely into Class A Ordinary Shares ("Share Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options, RSUs and any Class A Ordinary Shares acquired upon the exercise of Share Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service.

The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

Pursuant the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Class A Ordinary Shares received as a result of the exercise of Share Options or vesting of RSUs.

The acquisitions of the RSUs and Share Options reported on this form represent grants to each of Felix J. Baker, Dr. Biggar and M. Cantey Boyd of 2,026 RSUs on Table I and 12,158 Share Options on Table II. These grants, totaling 6,078 RSUs and 36,474 Share Options for Felix J. Baker, Dr. Biggar and M. Cantey Boyd in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

Includes beneficial ownership of 15,345 Class A Ordinary Shares received from vested RSUs each previously granted to Felix J. Baker and Dr. Biggar and 7,529 Class A Ordinary Shares received from vested RSUs previously granted to M. Cantey Boyd, in their capacity as directors of the Issuer.

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.

Includes 12,158 Share Options granted by the Issuer to each of Felix J. Baker, Dr. Biggar and M. Cantey Boyd on May 29, 2026, pursuant to the Incentive Award Plan. The Share Options have a strike price of $48.38 and vest in 12 equal monthly installments beginning on June 29, 2026 with the final installment vesting on the earlier of May 29, 2027 or the date of the next annual meeting of shareholders of the Issuer, subject to the applicable director's continuous service on the Board through the vesting date. The Share Options expire 10 years from the date of grant.

After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Class A Ordinary Shares reported in column 5 of Table I and the Share Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

Pursuant to the policies of the Adviser, Felix J. Baker, Dr. Biggar and M. Cantey Boyd do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified share options exercisable solely into Class A Ordinary Shares ("Share Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options, RSUs and any Class A Ordinary Shares acquired upon the exercise of Share Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service.

The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

Pursuant the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Class A Ordinary Shares received as a result of the exercise of Share Options or vesting of RSUs.

The acquisitions of the RSUs and Share Options reported on this form represent grants to each of Felix J. Baker, Dr. Biggar and M. Cantey Boyd of 2,026 RSUs on Table I and 12,158 Share Options on Table II. These grants, totaling 6,078 RSUs and 36,474 Share Options for Felix J. Baker, Dr. Biggar and M. Cantey Boyd in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.

The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.

The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

Includes 12,158 Share Options granted by the Issuer to each of Felix J. Baker, Dr. Biggar and M. Cantey Boyd on May 29, 2026, pursuant to the Incentive Award Plan. The Share Options have a strike price of $48.38 and vest in 12 equal monthly installments beginning on June 29, 2026 with the final installment vesting on the earlier of May 29, 2027 or the date of the next annual meeting of shareholders of the Issuer, subject to the applicable director's continuous service on the Board through the vesting date. The Share Options expire 10 years from the date of grant.

Pursuant to the policies of the Adviser, Felix J. Baker, Dr. Biggar and M. Cantey Boyd do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified share options exercisable solely into Class A Ordinary Shares ("Share Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options, RSUs and any Class A Ordinary Shares acquired upon the exercise of Share Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service.

The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

Pursuant the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Class A Ordinary Shares received as a result of the exercise of Share Options or vesting of RSUs.

The acquisitions of the RSUs and Share Options reported on this form represent grants to each of Felix J. Baker, Dr. Biggar and M. Cantey Boyd of 2,026 RSUs on Table I and 12,158 Share Options on Table II. These grants, totaling 6,078 RSUs and 36,474 Share Options for Felix J. Baker, Dr. Biggar and M. Cantey Boyd in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Class A Ordinary Shares reported in column 5 of Table I and the Share Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

Includes 2,026 restricted share units (each an "RSU") payable solely in Class A ordinary shares ("Class A Ordinary Shares") granted by Kiniksa Pharmaceuticals International, plc. (the "Issuer") to each of Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP"), and Dr. Stephen R. Biggar and M. Cantey Boyd, employees of Baker Bros. Advisors LP (the "Adviser"), on May 29, 2026, pursuant to the Issuer's 2018 Incentive Award Plan, as amended (the "Incentive Award Plan"). The RSUs fully vest on the earlier of May 29, 2027 or the date of the next annual meeting of shareholders of the Issuer, subject to the applicable director's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker, Dr. Biggar and M. Cantey Boyd serve on the Board as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

Pursuant to the policies of the Adviser, Felix J. Baker, Dr. Biggar and M. Cantey Boyd do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified share options exercisable solely into Class A Ordinary Shares ("Share Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options, RSUs and any Class A Ordinary Shares acquired upon the exercise of Share Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service.

The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

Pursuant the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Class A Ordinary Shares received as a result of the exercise of Share Options or vesting of RSUs.

The acquisitions of the RSUs and Share Options reported on this form represent grants to each of Felix J. Baker, Dr. Biggar and M. Cantey Boyd of 2,026 RSUs on Table I and 12,158 Share Options on Table II. These grants, totaling 6,078 RSUs and 36,474 Share Options for Felix J. Baker, Dr. Biggar and M. Cantey Boyd in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

Includes beneficial ownership of 15,345 Class A Ordinary Shares received from vested RSUs each previously granted to Felix J. Baker and Dr. Biggar and 7,529 Class A Ordinary Shares received from vested RSUs previously granted to M. Cantey Boyd, in their capacity as directors of the Issuer.

After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Class A Ordinary Shares reported in column 5 of Table I and the Share Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025.

This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025.

This transaction was executed in multiple trades through a broker-dealer at prices ranging between $53.765 and $54.22. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025.

This transaction was executed in multiple trades through a broker-dealer at prices ranging between $52.765 and $53.76. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025.

This transaction was executed in multiple trades through a broker-dealer at prices ranging between $54.00 and $54.155. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025.

This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025.

The option is fully vested and exercisable.

This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025.

The option is fully vested and exercisable.

This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025.

This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025.

This transaction was executed in multiple trades through a broker-dealer at prices ranging between $54.00 and $54.03. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025.

The option is fully vested and exercisable.

This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025.

This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025.

This transaction was executed in multiple trades through a broker-dealer at prices ranging between $54.00 and $54.225. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025.

The option is fully vested and exercisable.